Ra Capital Management, L.P. Eye Point Pharmaceuticals, Inc. Transaction History
Ra Capital Management, L.P.
- $4.82 Billion
- Q1 2025
A detailed history of Ra Capital Management, L.P. transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Ra Capital Management, L.P. holds 3,181,818 shares of EYPT stock, worth $33.4 Million. This represents 0.36% of its overall portfolio holdings.
Number of Shares
3,181,818
Previous 3,181,818
-0.0%
Holding current value
$33.4 Million
Previous $23.7 Million
27.25%
% of portfolio
0.36%
Previous 0.38%
Shares
5 transactions
Others Institutions Holding EYPT
# of Institutions
167Shares Held
72.5MCall Options Held
232KPut Options Held
207K-
Cormorant Asset Management, LP Boston, MA8.33MShares$87.3 Million4.79% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.8MShares$71.4 Million1.61% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.2MShares$65 Million0.07% of portfolio
-
Franklin Resources Inc San Mateo, CA4.15MShares$43.5 Million0.01% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA4.09MShares$42.9 Million0.05% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $357M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...